High efficiency transfection of porcine vascular cells in vitro with a synthetic vector system

被引:24
作者
Parkes, R
Meng, QH
Siapati, KE
McEwan, JR
Hart, SL
机构
[1] UCL, Inst Child Hlth, Mol Immunol Unit, London WC1N 1EH, England
[2] Royal Free & UCL, Sch Med, Hatter Inst, Cardiovasc Repair Remodelling Grp, London, England
关键词
gene therapy; non-viral; smooth muscle cells; endothelial cells; cardiovascular disease;
D O I
10.1002/jgm.265
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background Gene therapy strategies for the treatment of vascular disease such as the prevention of post-angioplasty restenosis require efficient, nontoxic transfection of vascular cells. In vitro studies in these cells contribute to vector development for in vivo use and for the evaluation of genes with therapeutic potential. The aim of this project was to evaluate a novel synthetic vector consisting of a liposome (L), an integrin targeting peptide (1), and plasmid DNA (D), which combine to form the LID vector complex. Methods Cultures of porcine smooth muscle cells and endothelial cells were established and then transfected with the LID vector, using the reporter genes luciferase and green fluorescent protein and the metalloprotease inhibitor TIMP-1. Results The LID vector system transfected primary porcine vascular smooth muscle cells and porcine aortic endothelial cells with efficiency levels of 40% and 35%, respectively. By increasing the relative DNA concentration four-fold, incubation periods as short as 30 min achieved the same levels of luciferase transgene expression as 4 h incubations at lower DNA concentrations. The transfection did not affect cell viability as measured by their proliferative potential. Serum levels of up to 20% in the transfection medium had no adverse affect on the efficiency of transfer and gene expression in either cell type. Transfections with the cDNA for TIMP-1 produced protein levels that peaked at 130 ng/ml per 24 h and persisted for 14 days at 10 ng/ml per 24 h. Conclusion This novel vector system has potential for studies involving gene transfer to cardiovascular cells in vitro and in vivo. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:292 / 299
页数:8
相关论文
共 20 条
[1]   Gene therapy for restenosis - Getting nearer the heart of the matter [J].
Baek, S ;
March, KL .
CIRCULATION RESEARCH, 1998, 82 (03) :295-305
[2]   Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 genes: Characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells [J].
Baker, AH ;
Wilkinson, GWG ;
Hembry, RM ;
Murphy, G ;
Newby, AC .
MATRIX BIOLOGY, 1996, 15 (06) :383-395
[3]   Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro - TIMP-3 promotes apoptosis [J].
Baker, AH ;
Zaltsman, AB ;
George, SJ ;
Newby, AC .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (06) :1478-1487
[4]   Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury [J].
Dollery, CM ;
Humphries, SE ;
McClelland, A ;
Latchman, DS ;
McEwan, JR .
CIRCULATION, 1999, 99 (24) :3199-3205
[5]   Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo [J].
Forough, R ;
Koyama, N ;
Hasenstab, D ;
Lea, H ;
Clowes, M ;
Nikkari, ST ;
Clowes, AW .
CIRCULATION RESEARCH, 1996, 79 (04) :812-820
[6]   Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein [J].
George, SJ ;
Johnson, JL ;
Angelini, GD ;
Newby, AC ;
Baker, AH .
HUMAN GENE THERAPY, 1998, 9 (06) :867-877
[7]   Integrin-mediated transfection with peptides containing arginine-glycine-aspartic acid domains [J].
Hart, SL ;
Collins, L ;
Gustafsson, K ;
Fabre, JW .
GENE THERAPY, 1997, 4 (11) :1225-1230
[8]  
HART SL, 1994, J BIOL CHEM, V269, P12468
[9]   Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector [J].
Hart, SL ;
Arancibia-Cárcamo, CV ;
Wolfert, MA ;
Mailhos, C ;
O'Reilly, NJ ;
Ali, RR ;
Coutelle, C ;
George, AJT ;
Harbottle, RP ;
Knight, AM ;
Larkin, DFP ;
Levinsky, RJ ;
Seymour, LW ;
Thrasher, AJ ;
Kinnon, C .
HUMAN GENE THERAPY, 1998, 9 (04) :575-585
[10]  
HART SL, 1995, GENE THER, V2, P552